Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Evunzekibart (ATOR-1017) in Advanced Solid Tumors
NCT04144842Phase 1Completed
- Sponsor
- Alligator Bioscience AB
- Start
- Dec 2019
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of evunzekibart in solid tumor, sponsored by Alligator Bioscience AB. Primary endpoints: Adverse events (AEs) assessed by CTCAE v 5.0 and Dose-limiting toxicities (DLTs). Started Dec 2019; status: completed.
02
Drugs
evunzekibart
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04144842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04144842.